Quantcast
Last updated on April 24, 2014 at 21:24 EDT

uniQure Named to MIT Technology Review’s 2013 50 Disruptive Companies List Recognizing World’s Most Innovative Companies

February 20, 2013

CAMBRIDGE, Massachusetts and AMSTERDAM, February 20, 2013 /PRNewswire/ –

uniQure has been identified in the field of biomedicine as one of 2013′s 50 Disruptive
Companies [http://www2.technologyreview.com/tr50/2012 ], MIT Technology Review
[http://www.technologyreview.com ]‘s annual list of the world’s most innovative technology
companies. The honorees are nominated by MIT Technology Review’s editors
[http://www.technologyreview.com/about/team/#Editorial ], who look for companies that have
demonstrated original and valuable technology over the last year, are bringing that
technology to market at significant scale, and are clearly influencing their competitors.
Spanning energy and materials, Internet and digital media, computing and communications,
biomedicine, and transportation, the 50 companies on the list represent the disruptive
innovations most likely to change our lives.

(Logo:
http://photos.prnewswire.com/prnh/20130220/595152 )

Jason Pontin, publisher and editor in chief of MIT Technology Review, states, “The
pace at which technology changes is astounding. This issue celebrates organizations at the
forefront, displaying ‘disruptive innovation’ that will prove to surpass the competition,
transform an industry, and change our lives. uniQure proves they are one of those
companies by restoring the promise of gene therapy with the approval to treat rare
metabolic disorders.”

uniQure [http://www.uniqure.com ] is the world leader in the development of human gene
based therapies. uniQure’s Glybera, a gene therapy for the treatment of lipoprotein lipase
deficiency was approved in the European Union in November 2012, and is the first approved
gene therapy in the Western world.

“We are honored by the recognition of MIT Technology Review,” says Jorn Aldag, CEO of
uniQure. “As one of the world’s leading technology publications, MIT Technology Review has
consistently succeeded in picking the technology and science leaders of the future -
disruptive innovators today and household names tomorrow. We believe that uniQure’s
advances will have a significant impact on the field of gene therapy. The power and
promise of gene therapy that inspire us every day are to provide permanent relief for a
broad range of diseases, instead of symptomatic treatments. Gene therapy has the potential
to transform the lives of millions of patients who cannot be treated today, and it harbors
the promise to prevent disease in the future. As such gene therapy constitutes a real
paradigm shift.”

uniQure and the other honorees will be featured in the March/April edition of MIT
Technology Review, available on newsstands worldwide March 5, and online at
technologyreview.com on February 20.

About uniQure

uniQure [http://www.uniqure.com ] is the world leader in the development of human gene
based therapies. uniQure’s Glybera, a gene therapy for the treatment of lipoprotein lipase
deficiency has been approved in the European Union, and is the first approved gene therapy
in the Western world. uniQure’s product pipeline of gene therapy products in development
comprise hemophilia B, acute intermittent porphyria, Parkinson’s disease and SanfilippoB.
Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for
therapeutic genes, the company has been able to design the world’s first stable and
scalable AAV manufacturing platform, validated in the approval process of Glybera. This
proprietary platform can be applied to a large number of rare (orphan) diseases caused by
one faulty gene. uniQure’s largest shareholders are Forbion Capital Partners and Gilde
Healthcare, two of the leading life sciences venture capital firms in the Netherlands.
Further information can be found at http://www.uniqure.com.

About MIT Technology Review

MIT Technology Review [http://www.technologyreview.com ] leads the global conversation
about technologies that matter. An independent global media company owned by the
Massachusetts Institute of Technology (MIT) [http://www.mit.edu ], the enterprise produces
publications read by millions of business leaders, innovators, thought leaders, and early
adopters around the globe, in six languages and on a variety of digital and print
platforms. The company publishes MIT Technology Review magazine
[http://www.technologyreview.com/magazine/2012/11 ], the world’s most respected technology
magazine (established 1899); daily news features, analysis, opinion, and video; and
Business Reports [http://www.technologyreview.com/magazine/businessreports ], which
explain how new technologies are transforming companies, disrupting markets, or creating
entirely new industries. It also produces live events
[http://www.technologyreview.com/events ] such as the annual EmTech MIT
[http://www2.technologyreview.com/emtech/12 ], international EmTech conferences, Summits,
and Salons. The company’s entrepreneurial community organization, the MIT Enterprise Forum
[http://www.mitef.org ], hosts over 400 events a year around the world.


    Photo: 

http://photos.prnewswire.com/prnh/20130220/595152

SOURCE uniQure


Source: PR Newswire